Helen Ward1, Minttu Rönn. 1. Department of Infectious Disease Epidemiology, Imperial College, London, UK. h.ward@imperial.ac.uk
Abstract
PURPOSE OF REVIEW: We review recent evidence about the link between sexually transmitted infections (STI) and HIV transmission and consider implications for control programmes. RECENT FINDINGS: New studies and meta-analyses confirm the association of HIV acquisition and transmission with recent STIs, although there is considerable heterogeneity between organisms and populations. Much of the recent evidence relates to herpes simplex virus type 2 (HSV-2), for which the population-attributable risk percentage (PAR%) for HSV-2 is between 25 and 35 in Africa. Mathematical models show how transmission attributable to STI varies with HIV epidemic phase, and HSV-2 becomes increasingly important as the epidemic matures. HSV-2 suppressive therapy reduces HIV concentrations in plasma and the genital tract in people coinfected with HSV-2, in part due to direct inhibition of HIV reverse transcriptase. Recent trials of HSV-2 suppressive therapy have not shown an impact on the risk of HIV acquisition, nor in controlling transmission from dually infected people to their serodiscordant heterosexual partners. SUMMARY: Although there is a plausible link between STI and HIV risk, intervention studies continue to be disappointing. This fact does not disprove a causal link, but mechanisms of action and the design and implementation of interventions need to be better understood.
PURPOSE OF REVIEW: We review recent evidence about the link between sexually transmitted infections (STI) and HIV transmission and consider implications for control programmes. RECENT FINDINGS: New studies and meta-analyses confirm the association of HIV acquisition and transmission with recent STIs, although there is considerable heterogeneity between organisms and populations. Much of the recent evidence relates to herpes simplex virus type 2 (HSV-2), for which the population-attributable risk percentage (PAR%) for HSV-2 is between 25 and 35 in Africa. Mathematical models show how transmission attributable to STI varies with HIV epidemic phase, and HSV-2 becomes increasingly important as the epidemic matures. HSV-2 suppressive therapy reduces HIV concentrations in plasma and the genital tract in people coinfected with HSV-2, in part due to direct inhibition of HIV reverse transcriptase. Recent trials of HSV-2 suppressive therapy have not shown an impact on the risk of HIV acquisition, nor in controlling transmission from dually infected people to their serodiscordant heterosexual partners. SUMMARY: Although there is a plausible link between STI and HIV risk, intervention studies continue to be disappointing. This fact does not disprove a causal link, but mechanisms of action and the design and implementation of interventions need to be better understood.
Authors: M J Wawer; N K Sewankambo; D Serwadda; T C Quinn; L A Paxton; N Kiwanuka; F Wabwire-Mangen; C Li; T Lutalo; F Nalugoda; C A Gaydos; L H Moulton; M O Meehan; S Ahmed; R H Gray Journal: Lancet Date: 1999-02-13 Impact factor: 79.321
Authors: A Kamali; M Quigley; J Nakiyingi; J Kinsman; J Kengeya-Kayondo; R Gopal; A Ojwiya; P Hughes; L M Carpenter; J Whitworth Journal: Lancet Date: 2003-02-22 Impact factor: 79.321
Authors: Sandra I McCoy; Joseph J Eron; Joann D Kuruc; Ronald P Strauss; Pia D M Macdonald; Susan A Fiscus; John Barnhart; Christopher D Pilcher; Peter A Leone; William C Miller Journal: Sex Transm Dis Date: 2009-06 Impact factor: 2.830
Authors: Jared M Baeten; Lara B Strick; Aldo Lucchetti; William L H Whittington; Jorge Sanchez; Robert W Coombs; Amalia Magaret; Anna Wald; Lawrence Corey; Connie Celum Journal: J Infect Dis Date: 2008-12-15 Impact factor: 5.226
Authors: Kristine E Johnson; Mark E Sherman; Victor Ssempiija; Aaron A R Tobian; Jonathan M Zenilman; Maire A Duggan; Godfrey Kigozi; David Serwadda; Maria J Wawer; Thomas C Quinn; Charles S Rabkin; Ronald H Gray Journal: AIDS Date: 2009-09-10 Impact factor: 4.177
Authors: H Grosskurth; F Mosha; J Todd; E Mwijarubi; A Klokke; K Senkoro; P Mayaud; J Changalucha; A Nicoll; G ka-Gina Journal: Lancet Date: 1995-08-26 Impact factor: 79.321
Authors: Esther E Freeman; Richard G White; Roel Bakker; Kate K Orroth; Helen A Weiss; Anne Buvé; Richard J Hayes; Judith R Glynn Journal: Vaccine Date: 2008-12-09 Impact factor: 3.641
Authors: Christina Gosmann; Melis N Anahtar; Scott A Handley; Mara Farcasanu; Galeb Abu-Ali; Brittany A Bowman; Nikita Padavattan; Chandni Desai; Lindsay Droit; Amber Moodley; Mary Dong; Yuezhou Chen; Nasreen Ismail; Thumbi Ndung'u; Musie S Ghebremichael; Duane R Wesemann; Caroline Mitchell; Krista L Dong; Curtis Huttenhower; Bruce D Walker; Herbert W Virgin; Douglas S Kwon Journal: Immunity Date: 2017-01-10 Impact factor: 31.745
Authors: Cassandra Tansey; Chunxia Zhao; Andre Hopkins; Jana M Ritter; Yetunde F Fakile; Allan Pillay; Samantha S Katz; Lara Pereira; James Mitchell; Frank Deyounks; Ellen N Kersh; Janet M McNicholl; Sundaram Ajay Vishwanathan Journal: J Infect Dis Date: 2018-03-13 Impact factor: 5.226
Authors: David A Katz; Julia C Dombrowski; Michael Barry; Dawn Spellman; Teal R Bell; Matthew R Golden Journal: J Acquir Immune Defic Syndr Date: 2019-04-15 Impact factor: 3.731
Authors: Harrell W Chesson; Kyle T Bernstein; Thomas L Gift; Julia L Marcus; Sharon Pipkin; Charlotte K Kent Journal: Sex Transm Dis Date: 2013-05 Impact factor: 2.830